Suchergebnisse - "Neoplasm Staging"

PubPharm (12)

1

Predictive value of renal tumor contour irregularity score in pathological T3a upstaging of clinical T1 renal cell carcinoma : A multi-institutional study

enthalten in: Urologic oncology | 2022

von Xu, P. | Zhang, S. | Cao, B. | +14

2

Accuracy of 68Ga-PSMA PET/CT for lymph node and bone primary staging in prostate cancer

enthalten in: Urologic oncology | 2022

von Moreira, L. | Mussi, T. | Cunha, M. | +2

3

Stage-specific conditional survival in renal cell carcinoma after nephrectomy

enthalten in: Urologic oncology | 2020

von Cheaib, J. | Patel, H. | Johnson, M. | +5

4

The prognostic value of zonal origin and extraprostatic extension of prostate cancer for biochemical recurrence after radical prostatectomy

enthalten in: Urologic oncology | 2019

von Takamatsu, K. | Matsumoto, K. | Shojo, K. | +9

5

Subclassification of pN3 staging systems for penile cancer : Proposal for modification of the current TNM classification

enthalten in: Urologic oncology | 2017

von Li, Z. | Guo, S. | Wu, Z. | +11

6

Multilocular cystic renal cell carcinoma : pathological t staging makes no difference to favorable outcomes and should be reclassified. Bhatt JR, Jewett MA, Richard PO, Kawaguchi S, Timilshina N, Evans A, Alibhai S, Finelli A.J Urol. November 2016;196(5):1350-1355

enthalten in: Urologic oncology | 2017

von Kryvenko, O.

CommentOn: J Urol. 2016 Nov;196 (5):1350-1355. - PMID 27341751

7

Lymph node density vs. the American Joint Committee on Cancer TNM nodal staging system in node-positive bladder cancer in patients undergoing extended or super-extended pelvic lymphadenectomy

enthalten in: Urologic oncology | 2017

von Lee, D. | Yoo, S. | You, D. | +7

8

The role of magnetic resonance image guided prostate biopsy in stratifying men for risk of extracapsular extension at radical prostatectomy. Raskolnikov D, George AK, Rais-Bahrami S, Turkbey B, Siddiqui MM, Shakir NA, Okoro C, Rothwax JT, Walton-Diaz A, Sankineni S, Su D, Stamatakis L, Merino MJ, Choyke PL, Wood BJ, Pinto PA. Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Center for Interventional Oncology, National Cancer Institute & Clinical Center, National Institutes of Health, Bethesda, Maryland; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Center for Interventional Oncology, National Cancer Institute & Clinical Center, National Institutes of Health, Bethesda, Maryland; e-mail : pintop@mail.nih.gov.J Urol. 2015 Jul;194(1):105-11. [Epub 2015 Jan 23]. doi: 10.1016/j.juro.2015.01.072

enthalten in: Urologic oncology | 2017

von Scott, E.

CommentOn: J Urol. 2015 Jul;194(1):105-111. - PMID 25623751

9

Risk of lymph node metastases in pathological gleason score≤6 prostate adenocarcinoma : Analysis of institutional and population-based databases

enthalten in: Urologic oncology | 2017

von Wenger, H. | Weiner, A. | Razmaria, A. | +2

10

Evidence of prostate cancer "reverse stage migration" toward more advanced disease at diagnosis : Data from the Pennsylvania Cancer Registry

enthalten in: Urologic oncology | 2016

von Reese, A. | Wessel, S. | Fisher, S. | +1